Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618227 | 0.82 | SSTR4 (0.34) | — | |
| SCHEMBL30527729 | 0.73 | CHEK1 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL25305763 | 0.73 | HTR2A (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL25306038 | 0.73 | CHEK1 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL31250340 | 0.73 | HTR2A (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL27159490 | 0.70 | SCN10A (0.32) | — | |
| SCHEMBL26126648 | 0.70 | CYP2D6 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL31232891 | 0.70 | CYP2D6 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL25308704 | 0.69 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL31250374 | 0.69 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CHRNB2 4847/4885CHRNA4 4788/4885CHRNB4 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.